Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in ...

The decision was supported by a randomised, six-week, placebo-controlled trial involving 316 adolescent subjects.

Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...

The European Commission (EC) has approved Danish CNS specialist Lundbeck (LUND: CO) and Otsuka Europe’s Rxulti ...

Rexulti (brexpiprazole) is already one of the two drugmakers’ fastest-growing products, and analysts have suggested that the new use could swell sales by $500 million to $1 billion, which would ...

while its new top product Rexulti (brexpiprazole) for agitation in Alzheimer's disease follows suit around the end of the decade. Rexulti has also been filed for approval as a treatment for post ...

Alembic Pharmaceuticals has received USFDA approval for its generic version of Brexpiprazole tablets, used to treat major depressive disorder. The approval covers strengths ranging from 0.25 mg to ...

Caliber recently launched 4 digital solutions that further strengthen its portfolio and also position the company at the ...

The IFPA Forum 2025 will unite stakeholders from across the Americas to address the urgent challenges faced by individuals ...

This came after Alkem Laboratories presented BE study protocol vide no. BIOS/2024/128, Version No. 01, Dated 17.07.2024 and ...